Literature DB >> 21435951

Protective immunity to pre-erythrocytic stage malaria.

Robert J Schwenk1, Thomas L Richie.   

Abstract

The development of a vaccine against malaria is a major research priority given the burden of disease, death and economic loss inflicted upon the tropical world by this parasite. Despite decades of effort, however, a vaccine remains elusive. The best candidate is a subunit vaccine termed RTS,S but this provides only partial protection against clinical disease. This review examines what is known about protective immunity against pre-erythrocytic stage malaria by considering the humoral and T cell-mediated immune responses that are induced by attenuated sporozoites and by the RTS,S vaccine. On the basis of these observations a set of research priorities are defined that are crucial for the development of a vaccine capable of inducing long-lasting and high-grade protection against malaria.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435951     DOI: 10.1016/j.pt.2011.02.002

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  23 in total

Review 1.  Global phenotypic screening for antimalarials.

Authors:  W Armand Guiguemde; Anang A Shelat; Jose F Garcia-Bustos; Thierry T Diagana; Francisco-Javier Gamo; R Kiplin Guy
Journal:  Chem Biol       Date:  2012-01-27

2.  Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity.

Authors:  Natalie M Bowman; Jonathan J Juliano; Cynthia J Snider; Oksana Kharabora; Steven R Meshnick; John Vulule; Chandy C John; Ann M Moormann
Journal:  Am J Trop Med Hyg       Date:  2016-08-01       Impact factor: 2.345

3.  Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.

Authors:  Kathrin Kastenmüller; Diego A Espinosa; Lauren Trager; Cristina Stoyanov; Andres M Salazar; Santosh Pokalwar; Sanjay Singh; Sheetij Dutta; Christian F Ockenhouse; Fidel Zavala; Robert A Seder
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

Review 4.  Impact of filarial infections on coincident intracellular pathogens: Mycobacterium tuberculosis and Plasmodium falciparum.

Authors:  Simon Metenou; Subash Babu; Thomas B Nutman
Journal:  Curr Opin HIV AIDS       Date:  2012-05       Impact factor: 4.283

5.  Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.

Authors:  Michael D Porter; Jennifer Nicki; Christopher D Pool; Margot DeBot; Ratish M Illam; Clara Brando; Brooke Bozick; Patricia De La Vega; Divya Angra; Roberta Spaccapelo; Andrea Crisanti; Jittawadee R Murphy; Jason W Bennett; Robert J Schwenk; Christian F Ockenhouse; Sheetij Dutta
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

6.  Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.

Authors:  Lais H Teixeira; Cibele A Tararam; Marcio O Lasaro; Ariane G A Camacho; Jonatan Ersching; Monica T Leal; Sócrates Herrera; Oscar Bruna-Romero; Irene S Soares; Ruth S Nussenzweig; Hildegund C J Ertl; Victor Nussenzweig; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

7.  Analysis of the immune response of a new malaria vaccine based on the modification of cryptic epitopes.

Authors:  Yan Shen; Jun Wang; Yuxiao Huang; Jiao Liang; Xuewu Liu; Dudu Wu; He Jiang; Ya Zhao; Yinghui Li
Journal:  Parasitol Res       Date:  2016-01-30       Impact factor: 2.289

8.  Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe.

Authors:  Susanne H Sheehy; Alexandra J Spencer; Alexander D Douglas; B Kim Lee Sim; Rhea J Longley; Nick J Edwards; Ian D Poulton; Domtila Kimani; Andrew R Williams; Nicholas A Anagnostou; Rachel Roberts; Simon Kerridge; Merryn Voysey; Eric R James; Peter F Billingsley; Anusha Gunasekera; Alison M Lawrie; Stephen L Hoffman; Adrian V S Hill
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

9.  Drugs for malaria: something old, something new, something borrowed.

Authors:  Charlotte Hobbs; Patrick Duffy
Journal:  F1000 Biol Rep       Date:  2011-11-01

10.  Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Authors:  Caroline Ogwang; Muhammed Afolabi; Domtila Kimani; Ya Jankey Jagne; Susanne H Sheehy; Carly M Bliss; Christopher J A Duncan; Katharine A Collins; Miguel A Garcia Knight; Eva Kimani; Nicholas A Anagnostou; Eleanor Berrie; Sarah Moyle; Sarah C Gilbert; Alexandra J Spencer; Peninah Soipei; Jenny Mueller; Joseph Okebe; Stefano Colloca; Riccardo Cortese; Nicola K Viebig; Rachel Roberts; Katherine Gantlett; Alison M Lawrie; Alfredo Nicosia; Egeruan B Imoukhuede; Philip Bejon; Britta C Urban; Katie L Flanagan; Katie J Ewer; Roma Chilengi; Adrian V S Hill; Kalifa Bojang
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.